Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Dactolisib colon cancer sensitive detail...
APC inact mut Sirolimus colon cancer sensitive detail...
APC inact mut Vinorelbine colon cancer sensitive detail...
APC inact mut Vandetanib colon cancer sensitive detail...
TP53 wild-type Adavosertib + PF-00477736 colon cancer sensitive detail...
FBXW7 loss Sirolimus colon cancer sensitive detail...
APC inact mut CGP049090 colon cancer sensitive detail...
APC inact mut ICG-001 colon cancer sensitive detail...
APC inact mut MF tricyclic colon cancer sensitive detail...
APC inact mut PKF115-584 colon cancer sensitive detail...
APC inact mut StAx-35 colon cancer sensitive detail...
BRAF V600E PD-0325901 colon cancer sensitive detail...
TP53 wild-type SAR405838 colon cancer sensitive detail...
NRAS exon2 Cetuximab colon cancer resistant detail...
NRAS exon2 Panitumumab colon cancer resistant detail...
PIK3CA mutant PWT33597 colon cancer sensitive detail...
BRAF V600E Gedatolisib colon cancer sensitive detail...
APC inact mut iCRT-3 colon cancer sensitive detail...
APC inact mut JW55 colon cancer sensitive detail...
APC inact mut iCRT-5 colon cancer sensitive detail...
APC inact mut iCRT-14 colon cancer sensitive detail...
APC inact mut G007-LK colon cancer sensitive detail...
FGFR2 amp Ponatinib colon cancer sensitive detail...
FGFR2 amp Dovitinib colon cancer sensitive detail...
FGFR2 amp Cediranib colon cancer sensitive detail...
FGFR2 amp Nintedanib colon cancer sensitive detail...
FGFR2 amp Brivanib colon cancer no benefit detail...
FGFR2 wild-type Ponatinib colon cancer resistant detail...
BRAF V600E Navitoclax + Vemurafenib colon cancer sensitive detail...
BRAF V600E Navitoclax + Trametinib colon cancer sensitive detail...
TP53 wild-type CPUY201112 colon cancer sensitive detail...
TP53 loss CPUY201112 colon cancer decreased response detail...
PTEN loss KU-55933 colon cancer sensitive detail...
APC wild-type CTNNB1 wild-type Vantictumab colon cancer predicted - sensitive detail...
BRAF V600E Cetuximab colon cancer resistant detail...
TP53 wild-type Trifluridine colon cancer sensitive detail...
BRAF V600E GDC0879 colon cancer sensitive detail...
BRAF N581Y GDC0879 colon cancer resistant detail...
NRAS mutant GDC0879 colon cancer resistant detail...
BRAF V600E PLX4720 colon cancer sensitive detail...
TP53 wild-type KRT-232 colon cancer sensitive detail...
TP53 wild-type KRT-232 + Radiotherapy colon cancer sensitive detail...
FGFR2 amp AZD4547 colon cancer sensitive detail...
BRAF V600E Panitumumab colon cancer resistant detail...
FGFR2 amp Infigratinib colon cancer sensitive detail...
BRAF mutant Selumetinib colon cancer predicted - sensitive detail...
BRAF mutant PF-00477736 + PF3644022 colon cancer predicted - sensitive detail...
PIK3CA E545K LY2780301 colon cancer sensitive detail...
CTNNB1 over exp NVP-TNKS656 + Triciribine colon cancer predicted - sensitive detail...
BRAF V600E TP53 Q192K Panitumumab + Vemurafenib colon cancer predicted - sensitive detail...
MLH1 loss KU60648 colon cancer sensitive detail...
MSH6 loss KU60648 colon cancer no benefit detail...
CHEK1 positive CCT244747 + Gemcitabine colon cancer predicted - sensitive detail...
BRAF V600E Cetuximab + Sorafenib colon cancer predicted - sensitive detail...
TP53 loss CHIR-124 + SN-38 colon cancer sensitive detail...
NRAS exon3 Cetuximab colon cancer resistant detail...
NRAS exon4 Cetuximab colon cancer resistant detail...
NRAS exon3 Panitumumab colon cancer resistant detail...
NRAS exon4 Panitumumab colon cancer resistant detail...
FGFR2 - COL14A1 FGFR2 amp Derazantinib colon cancer sensitive detail...
FGFR2 fusion FGFR1 amp Debio 1347 colon cancer predicted - sensitive detail...
FGFR2 - INA Debio 1347 colon cancer predicted - sensitive detail...
BRAF K601E MAP2K1 V211D Binimetinib + Panitumumab colon cancer predicted - resistant detail...
BRAF K601E MAP2K1 V211D MAP855 colon cancer sensitive detail...
BRAF K601E MAP2K1 V211D Binimetinib colon cancer resistant detail...
BRAF K601E MAP2K1 V211D Binimetinib + Cetuximab colon cancer resistant detail...
MLH1 mutant N/A colon cancer not applicable detail...
MSH6 mutant N/A colon cancer not applicable detail...
RET fusion Pralsetinib colon cancer predicted - sensitive detail...
FGFR1 over exp Rogaratinib colon cancer sensitive detail...
FGFR2 amp FGFR2 over exp Rogaratinib colon cancer sensitive detail...
FBXW7 loss unspecified PD-1 antibody colon cancer predicted - resistant detail...
PIK3CA H1047R T-2143 colon cancer sensitive detail...
BRAF V600K PLX8394 colon cancer sensitive detail...
BRAF V600E Cetuximab + Encorafenib colon cancer sensitive detail...
BRAF V600E Encorafenib + Panitumumab colon cancer sensitive detail...
BRAF wild-type Panitumumab colon cancer predicted - sensitive detail...
NRAS wild-type Panitumumab colon cancer predicted - sensitive detail...
NRAS wild-type Cetuximab colon cancer predicted - sensitive detail...
BRAF wild-type Cetuximab colon cancer predicted - sensitive detail...
RB1 positive SHR6390 colon cancer sensitive detail...
MSH6 negative Dostarlimab-gxly colon cancer sensitive detail...
MLH1 negative Dostarlimab-gxly colon cancer sensitive detail...
MSH6 negative Ipilimumab + Nivolumab colon cancer sensitive detail...
MLH1 negative Ipilimumab + Nivolumab colon cancer sensitive detail...
MLH1 negative Pembrolizumab colon cancer sensitive detail...
MSH6 negative Pembrolizumab colon cancer sensitive detail...
MSH6 negative Nivolumab colon cancer sensitive detail...
MLH1 negative Nivolumab colon cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01274624 Phase I Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Pelareorep Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer Completed USA 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01966289 Phase I Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) Completed USA 0
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02041481 Phase I Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed USA 0
NCT02448173 Phase III A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer Recruiting USA 0
NCT02508077 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Terminated USA 0
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN 1
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA 3
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA 5
NCT02834052 Phase Ib/II Pembrolizumab + Poly ICLC Pembrolizumab + Poly-ICLC in MRP Colon Cancer Recruiting USA 0
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed USA 1
NCT02980029 Phase I TVB-2640 Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer Recruiting USA 0
NCT03127098 Phase Ib/II ALT-803 + ETBX-011 QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Completed USA 0
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting USA 14
NCT03317119 Phase I Trametinib + Trifluridine-tipiracil hydrochloride Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03631641 Phase II Nivolumab Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Active, not recruiting USA 0
NCT03711058 Phase Ib/II Copanlisib + Nivolumab Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer Recruiting USA 0
NCT03827967 Phase I PalloV-CC Trial of PalloV-CC in Colon Cancer Recruiting USA 0
NCT03829410 Phase Ib/II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Recruiting USA 0
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA 1
NCT03919292 Phase Ib/II Divalproex sodium + Neratinib Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Recruiting USA 0
NCT04294160 Phase I Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer Recruiting USA | CAN 8
NCT04486378 Phase II RO7198457 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Recruiting USA 3
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04799431 Phase I Neoantigen peptide vaccine + Poly ICLC + Retifanlimab Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer Not yet recruiting USA 0